trending Market Intelligence /marketintelligence/en/news-insights/trending/KB4axvDKEK6FEDaDEOzjoQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Ionis Pharmaceutical licenses experimental Alzheimer's therapy to Biogen

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Ionis Pharmaceutical licenses experimental Alzheimer's therapy to Biogen

Ionis Pharmaceuticals Inc. has licensed its experimental Alzheimer's disease therapy IONIS-MAPTrx to Biogen Inc.

Ionis earned $45 million from the licensing fee, with the possibility of receiving an additional $155 million in milestone payments, according to a Dec. 19 press release. Ionis, which develops RNA-targeted therapeutics, will also be eligible to receive future royalty payments in the low- to mid-teens based on sales of the medicine.

The agreement continues the companies' partnership in developing treatments for neurological disorders.

IONIS-MAPTrx is an antisense therapy that is designed to reduce the production of what is called microtubule-associated protein tau in the central nervous system. Microtubule-associated protein tau is thought to contribute or be the cause of multiple neurodegenerative diseases, including Alzheimer's disease and some forms of frontotemporal degeneration, according to Ionis.

Carlsbad, Calif.-based Ionis will be responsible for a current phase 1 clinical study of IONIS-MAPTrx in patients with mild Alzheimer's disease, which began in 2017. The company will also be responsible for a one-year long-term extension study that began in 2019.

Biogen will be responsible for any future studies of IONIS-MAPTrx and any further development, including regulatory filings and commercialization of the medicine, according to the press release.